Caring Ambassadors Hepatitis C Program Newsletter

www.HepCChallenge.org

October 2009

Clinical Trials, Cohort Studies, Pilot Studies

 

Lack of association between hepatitis C infection and chronic kidney disease. Asrani SK, Buchanan P, Pinsky B, Rey LR, Schnitzler M, Kanwal F. Clin Gastroenterol Hepatol. 2009 Sep 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Asrani%20SK%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Osburn WO, Fisher BE, Dowd KA, et al. Gastroenterology. 2009 Sep 23. [Epub ahead of print]   

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Osburn%20WO%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Randomized study of peginterferon-alpha2a plus ribavirin versus peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Rumi M, Aghemo A, Prati GM, et al. Gastroenterology. 2009 Sep 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rumi%20M%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Morin T, Pariente A, Lahmek P, et al. Eur J Gastroenterol Hepatol. 2009 Sep 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morin%20T%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Induction pegylated interferon Alfa-2b in combination with ribavirin in patients with genotype 1 and 4 chronic hepatitis C: A prospective, randomized, multi-center, open-label study. Brady DE, Torres DM, An JW, et al. Clin Gastroenterol Hepatol. 2009 Sep 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Brady%20DE%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study. Morisco F, Stroffolini T, Medda E, et al. J Viral Hepat. 2009 Sep 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morisco%20F%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

 

 

Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Corey KE, Servoss JC, Casson DR, et al. Infect Control Hosp Epidemiol. 2009 Oct;30(10):1000-5.           

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Corey%20KE%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Effect of HCV RNA suppression during peginterferon Alfa-2A maintenance therapy on clinical outcomes in the HALT-C Trial. Shiffman ML, Morishima C, Dienstag JL, et al. Gastroenterology. 2009 Sep 9. [Epub ahead of print]   

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shiffman%20ML%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Natural killer cells are polarized towards cytotoxicity in chronic hepatitis C in an interferon-alpha-dependent manner. Ahlenstiel G, Titerence RH, Koh C, et al. Gastroenterology. 2009 Sep 9. [Epub ahead of print]           

http://www.ncbi.nlm.nih.gov/pubmed/19747917?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Dore GJ, Hellard M, Matthews G, et al. Gastroenterology. 2009 Sep 23. [Epub ahead of print]          

http://www.ncbi.nlm.nih.gov/pubmed/19782085?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Reduction in neutrophil count during hepatitis C treatment: Drug toxicity or predictor of good response? Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Dig Dis Sci. 2009 Sep 16. [Epub ahead of print]   

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Alvarez-Uria%20G%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Basic and Applied Science, Pre-Clinical Studies

 

Full length characterisation of hepatitis C Virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection. Humphreys I, Fleming V, Fabris P, et al. J Virol. 2009 Sep 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Humphreys%20I%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors. Chase R, Skelton A, Xia E, et al. Antiviral Res. 2009 Sep 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chase%20R%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Kluwe J, Pradere JP, Gwak GY, et al. Gastroenterology. 2009 Sep 23. [Epub ahead of print]          

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kluwe%20J%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry. Li HF, Huang CH, Ai LS, Chuang CK, Chen SS. J Biomed Sci. 2009 Sep 24;16(1):89. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Li%20HF%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection. Moorman J, Dong ZP, Ni L, Zhang C, Borthwick T, Yao ZQ. Immunology. 2009 Oct;128(2):227-35.    

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Moorman%20J%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. Simister P, Schmitt M, Geitmann M, et al. J Virol. 2009 Sep 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Simister%20P%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein. Analysis using mouse model and cultured cells. Moriya K, Miyoshi H, Tsutsumi T, et al. Am J Pathol. 2009 Sep 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Moriya%20K%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women. Dryer PD, Limketkai BN, Martin CM, et al. J Antimicrob Chemother. 2009 Sep 18. [Epub ahead of print]      

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Dryer%20PD%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

 

HIV/HCV Coinfection

 

Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. Spradling PR, Richardson JT, Buchacz K, et al.  J Acquir Immune Defic Syndr. 2009 Sep 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Spradling%20PR%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. Marks KM, Clarke RM, Bussel JB, Talal AH, Glesby MJ. J Acquir Immune Defic Syndr. 2009 Sep 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Marks%20KM%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Mira JA, Gutiérrez-Valencia A, Gil Ide L, et al. Clin Infect Dis. 2009 Oct 15;49(8):e84-91.

http://www.ncbi.nlm.nih.gov/pubmed/19772388?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.

Pineda JA, Aguilar-Guisado M, Rivero A, et al. Clin Infect Dis. 2009 Oct 15;49(8):1274-82.

http://www.ncbi.nlm.nih.gov/pubmed/19772387?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers.

Sánchez-Conde M, Montes-Ramírez ML, Miralles P, et al. J Viral Hepat. 2009 Sep 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22S%C3%A1nchez-Conde%20M%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? Winston A, Garvey L, Scotney E, et al. J Viral Hepat. 2009 Sep 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Winston%20A%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. Reiberger T, Ferlitsch A, Sieghart W, et al. J Viral Hepat. 2009 Sep 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19780945?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. Balagopal A, Ray SC, De Oca RM, et al. AIDS. 2009 Sep 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Balagopal%20A%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Neukam K, Recio E, Camacho A, et al. Eur J Gastroenterol Hepatol. 2009 Sep 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19773664?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Inability to access addiction treatment and risk of HIV infection among injection drug users recruited from a supervised injection facility. Milloy MJ, Kerr T, Zhang R, Tyndall M, Montaner J, Wood E. J Public Health (Oxf). 2009 Sep 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Milloy%20MJ%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Complementary and Alternative Medicine

 

Xanthohumol enhances antiviral effect of interferon alpha-2b against bovine viral diarrhea virus, a surrogate of hepatitis C virus. Zhang N, Liu Z, Han Q, Chen J, Lv Y. Phytomedicine. 2009 Sep 10. [Epub ahead of print] 

http://www.ncbi.nlm.nih.gov/pubmed/19748253?ordinalpos=10&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Complementary and alternative medicine use in chronic liver disease patients. Ferrucci LM, Bell BP, Dhotre KB, et al. J Clin Gastroenterol. 2009 Sep 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ferrucci%20LM%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Silymarin inhibits in vitro T cell proliferation and cytokine production in hepatitis C virus infection. Morishima C, Shuhart MC, Wang CC, et al. Gastroenterology. 2009 Sep 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19782083?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Toxicology and biodistribution study of CIGB-230, a DNA vaccine against hepatitis C virus.

Bacardí D, Amador-Cañizares Y, Cosme K, et al. Hum Exp Toxicol. 2009 Sep 7. [Epub ahead of print]     

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bacard%C3%AD%20D%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels. Seo YS, Jung ES, An H, et al. [ ]38: Liver Int. 2009 Sep 2. [Epub ahead of print]           

http://www.ncbi.nlm.nih.gov/pubmed/19725889?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Clinical case registries: Simultaneous local and national disease registries for population quality management. Backus LI, Gavrilov S, Loomis TP, et al.  J Am Med Inform Assoc. 2009 Aug 28. [Epub ahead of print]   

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Backus%20LI%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. Page K, Hahn JA, Evans J, et al. J Infect Dis. 2009 Oct 15;200(8):1216-26.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Page%20K%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. McGovern BH, Birch CE, Bowen MJ, et al. Clin Infect Dis. 2009 Oct 1;49(7):1051-60.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22McGovern%20BH%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

The impact of the prevention programme of hepatitis C over more than a decade: the French experience. Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, et al. J Viral Hepat. 2009 Sep 23. [Epub ahead of print] 

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Delarocque-Astagneau%20E%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Depression and protective factors of mental health in people with hepatitis C: A questionnaire survey. Erim Y, Tagay S, Beckmann M, et al. Int J Nurs Stud. 2009 Sep 18. [Epub ahead of print]           

http://www.ncbi.nlm.nih.gov/pubmed/19766994?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Predicting clinical and histological outcomes based on standard laboratory tests in advanced chronic hepatitis C. Ghany MG, Lok AS, Everhart JE, et al. Gastroenterology. 2009 Sep 17. [Epub ahead of print]          

http://www.ncbi.nlm.nih.gov/pubmed/19766643?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Combined effects of alcohol and hepatitis C: A secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Plebani JG, Tirado CF, Pettinati HM, et al. Addict Behav. 2009 Sep 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Plebani%20JG%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Managing depression during hepatitis C treatment. Sockalingam S, Abbey SE. Can J Psychiatry. 2009 Sep;54(9):614-25.       

http://www.ncbi.nlm.nih.gov/pubmed/19751550?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum